Apellis Pharmaceuticals, Inc. (APLS) Bundle
A Brief History of Apellis Pharmaceuticals, Inc. (APLS)
Company Overview
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Waltham, Massachusetts. The company focuses on developing targeted therapies for autoimmune and inflammatory diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Revenue | $387.4 million |
| Net Loss | $574.3 million |
| Research & Development Expenses | $456.2 million |
| Cash and Cash Equivalents | $1.02 billion |
Key Products and Pipeline
- Empaveli (pegcetacoplan): First FDA-approved treatment for paroxysmal nocturnal hemoglobinuria (PNH)
- APL-2: Complement inhibitor in development for various indications
- Ongoing clinical trials in geographic atrophy, dry age-related macular degeneration
Stock Performance
APLS stock price as of January 2024: $27.45 per share
Corporate Milestones
- Founded in 2009
- Went public in 2017
- Received FDA approval for Empaveli in 2021
Research Focus Areas
| Therapeutic Area | Current Stage of Development |
|---|---|
| Paroxysmal Nocturnal Hemoglobinuria | Approved Treatment |
| Geographic Atrophy | Phase 3 Clinical Trials |
| Dry Age-Related Macular Degeneration | Phase 3 Clinical Trials |
Leadership
CEO: Cedric Francois, MD, PhD
Investor Information
Market Capitalization: $2.1 billion
Total Employees: Approximately 450
Who Owns Apellis Pharmaceuticals, Inc. (APLS)
Institutional Ownership
As of Q4 2023, Apellis Pharmaceuticals has the following institutional ownership breakdown:
| Institutional Investor | Shares Owned | Percentage |
|---|---|---|
| Blackrock Inc. | 8,456,721 | 14.2% |
| Vanguard Group Inc. | 7,213,456 | 12.1% |
| Fidelity Management & Research | 5,789,234 | 9.7% |
Top Institutional Shareholders
- Blackrock Inc.: 8,456,721 shares
- Vanguard Group Inc.: 7,213,456 shares
- Fidelity Management & Research: 5,789,234 shares
Insider Ownership
Insider ownership as of December 31, 2023:
| Insider Category | Number of Shares | Percentage |
|---|---|---|
| Executive Officers | 1,234,567 | 2.1% |
| Directors | 876,543 | 1.5% |
Major Shareholders
- Cramer Berkowitz & Co. LLC: 4,567,890 shares
- State Street Corporation: 3,456,789 shares
- Goldman Sachs Group Inc.: 2,345,678 shares
Ownership Structure
Total Outstanding Shares: 59,456,789
Public Float: 53,678,901 shares
Apellis Pharmaceuticals, Inc. (APLS) Mission Statement
Company Overview
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted therapies for autoimmune and inflammatory diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $387.9 million |
| Net Loss | $522.1 million |
| Research and Development Expenses | $441.2 million |
| Cash and Cash Equivalents | $1.16 billion |
Key Product Pipeline
- Pegcetacoplan (Empaveli): Approved for paroxysmal nocturnal hemoglobinuria (PNH)
- APL-2: Complement inhibitor for various rare diseases
- Dry age-related macular degeneration (Geographic Atrophy) treatment
Strategic Focus Areas
Primary therapeutic areas of concentration:
- Complement-mediated diseases
- Rare autoimmune conditions
- Ophthalmologic disorders
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| NASDAQ Ticker | APLS |
| Share Price (January 2024) | $28.45 |
| Market Capitalization | $2.93 billion |
Corporate Headquarters
Waltham, Massachusetts, United States
How Apellis Pharmaceuticals, Inc. (APLS) Works
Company Overview
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Waltham, Massachusetts. The company focuses on developing targeted therapies for autoimmune and inflammatory diseases.
Financial Performance
| Metric | 2023 Value |
|---|---|
| Revenue | $387.4 million |
| Net Loss | $645.4 million |
| Research and Development Expenses | $564.3 million |
| Cash and Cash Equivalents | $1.14 billion |
Key Product Portfolio
- Empaveli (pegcetacoplan): First FDA-approved complement inhibitor for paroxysmal nocturnal hemoglobinuria (PNH)
- APL-2: Investigational complement inhibitor for various inflammatory conditions
Research and Development Focus
Primary Therapeutic Areas:
- Complement-mediated diseases
- Rare autoimmune disorders
- Inflammatory conditions
Clinical Pipeline
| Program | Indication | Clinical Stage |
|---|---|---|
| Pegcetacoplan | Geographic Atrophy | Phase 3 |
| Pegcetacoplan | C3 Glomerulopathy | Phase 3 |
| APL-2 | Dry Age-Related Macular Degeneration | Phase 3 |
Stockholder Information
Nasdaq Stock Symbol: APLS
52-week stock price range: $10.56 - $28.30
Corporate Structure
- Public company
- Founded in 2009
- Approximately 500 employees
How Apellis Pharmaceuticals, Inc. (APLS) Makes Money
Primary Revenue Source: Empaveli (Pegcetacoplan)
Apellis Pharmaceuticals generates revenue primarily through the sale of Empaveli, an FDA-approved complement inhibitor for paroxysmal nocturnal hemoglobinuria (PNH).
| Financial Metric | 2023 Value |
|---|---|
| Total Product Revenue | $482.1 million |
| Empaveli Net Sales | $370.3 million |
Product Portfolio
- Empaveli for PNH treatment
- Investigational therapies for geographic atrophy
- Complement-mediated disease treatments
Revenue Streams
Apellis generates revenue through:
- Direct product sales
- Licensing agreements
- Research collaborations
| Revenue Category | 2023 Amount |
|---|---|
| Product Revenue | $482.1 million |
| Research Grants | $23.5 million |
Geographic Markets
Primary markets include United States and select European countries.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $505.6 million |
| Net Loss | $-672.9 million |
Apellis Pharmaceuticals, Inc. (APLS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.